Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 21, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
September 13, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
August 13, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related...
Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
August 11, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17th at 9:00 AM ET ...
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
August 03, 2021 06:00 ET
|
Outlook Therapeutics, Inc.
In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key secondary (p = 0.0043) efficacy endpoints with 41% of subjects gaining at least 15...
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
July 07, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Experienced executive with a track-record of successful eye care product launchesAppointment reflects Outlook Therapeutics’ dedication to transition to commercial-stage company ISELIN, N.J., July ...
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
June 14, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic...
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
June 08, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Topline readout of data from NORSE TWO targeted for calendar Q3 2021New Biologics License Application (BLA) filing anticipated in calendar Q1 2022 ISELIN, N.J., June 08, 2021 (GLOBE NEWSWIRE)...
Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010
May 27, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Drs. Mark Humayun and Firas Rahhal, leading retinal specialists and Advisors to Outlook Therapeutics, stress clinical value of ONS-5010, if approved, over existing treatment options Registration...